Danaher slides as Masimo buyout financing and integration worries pressure sentiment
Danaher shares fell as investors repriced deal risk and leverage concerns tied to its agreed $9.9B all-cash acquisition of Masimo. The decline followed renewed focus on financing with debt, integration uncertainty, and the possibility of regulatory or timing delays into the second half of 2026.
1. What’s moving the stock
Danaher (DHR) traded lower as the market refocused on the company’s pending purchase of Masimo in a roughly $9.9 billion all-cash transaction priced at $180 per share. With the close expected in the second half of 2026, investors are discounting uncertainty around financing, execution, and the risk of delays that can keep an overhang on the stock for months. (finance.yahoo.com)
2. Why investors are pressing the sell button today
The selloff reflects familiar M&A math: Danaher is taking on a large purchase price relative to near-term contribution, and it has indicated the deal will be funded with cash and debt—raising sensitivity to rates and leverage optics. Traders are also pricing integration complexity as Masimo expands Danaher’s diagnostics footprint into patient monitoring, where realizing synergies can take time. (ainvest.com)
3. What to watch next
Near-term catalysts are deal-process milestones—shareholder approval and regulatory clearances—and any updated expectations on timing or financing. Until those checkpoints are cleared, DHR can trade more on perceived probability of closing than on longer-term strategic benefits. (investor.masimo.com)